The purpose of our business responsibility is to help our customers develop and produce medical drugs better and more efficiently. So more people will have access to better medicine.
Access to Medication
It is Sartorius mission to enable better health for more people. Manufacturing biopharmaceuticals is complex, time-consuming and cost-intensive. We are helping our customers from the biotech industry to develop and manufacture medications from the first idea to production – faster, safer and more efficiently.
In established countries, many people suffer from diseases for which there is still no effective treatment. Examples include types of cancer, Alzheimer’s disease or dementia, autoimmune diseases and congenital metabolic disorders, as well as infectious diseases. In developing countries and emerging markets, the availability and affordability of healthcare is considerably below global standards. More than half of the world’s population has either no access or inadequate healthcare. Every day, people die of diseases that are both preventable and treatable.
Our diverse technologies enable us to offer our biopharmaceutical customers an integrated approach toward optimizing the process of developing and manufacturing medicines. This ensures that essential vaccines and innovative medications reach the market faster, at a higher quality, in greater numbers and at lower prices to improve availability in existing and emerging markets.
Often, new approaches arise from interdisciplinary collaboration among various experts. As one of the leading companies in our sector, our approach is to bring together leaders from the scientific community, startups and industry, and foster an ongoing exchange of ideas and opportunities. As a result, this often yields new and creative ideas supporting scientific advancements. Sartorius maintains relationships with approximately 120 scientific partners worldwide.
For more than 10 years, the Upstream & Downstream Forum has been a venue for discussing the latest technical and scientific approaches in downstream processing that accelerate development and optimize production of vaccines and biopharmaceuticals. The event continues to build upon the collaborative bridge between upstream and downstream specialists.
With the Research Xchange Forum, Sartorius created a platform for interdisciplinary exchanges between industry and science. The second Research Xchange Forum in March 2018 focused on sharing knowledge and ideas on regenerative medicine and cell therapy.
In 2018, Sartorius also launched the Life Science Factory gGmbH, an independent, non-profit entity that promotes scientific research in life sciences. The mission is to strengthen the research and development of innovative technologies with a clear application focus. This cooperative project ensures that current research can be implemented quickly and effectively to address the needs of patients with unmet medical needs.